Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy
Ming Huang, Moritz Lassé, Silke Dehde, Felicitas E. Hengel, Fatih Demir, Anja M. Billing, Ning Song, Larissa Seifert, Oliver Kretz, Florian Grahammer, Ulf Panzer, Sebastian Brähler, Tobias B. Huber, Gunther Zahner, Markus M. Rinschen, Nicola M. Tomas
Ming Huang, Moritz Lassé, Silke Dehde, Felicitas E. Hengel, Fatih Demir, Anja M. Billing, Ning Song, Larissa Seifert, Oliver Kretz, Florian Grahammer, Ulf Panzer, Sebastian Brähler, Tobias B. Huber, Gunther Zahner, Markus M. Rinschen, Nicola M. Tomas
View: Text | PDF
Research Article Cell biology Immunology Nephrology

Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy

  • Text
  • PDF
Abstract

Although the pathogenic role of autoantibodies targeting the podocyte protein THSD7A in membranous nephropathy (MN) is well described, the consequences of autoantibody binding for podocyte homeostasis and the function of THSD7A remain unclear. Here, we induced an MN model in control and podocyte-specific Thsd7a-KO (Thsd7a–/–) mice using rabbit anti-THSD7A antibodies, followed by transcriptome and proteome analyses. Anti-THSD7A antibodies in WT mice caused significant loss of key slit diaphragm (SD) proteins, such as nephrin and NEPH1, without transcriptional downregulation. Glomeruli showed substantial transcriptomic and proteomic reconfiguration indicative of extensive podocyte injury, including disruptions in podocyte adhesion, cytoskeletal dynamics, and marked upregulation of ubiquitin-proteasome system components, cathepsins, and ADAM proteases. Notably, experiments in C3-deficient mice revealed that proteolytic activation and SD protein loss are driven by complement-independent pathways. Thsd7a–/– mice only displayed a mild phenotype under basal conditions, and they were completely protected from MN development upon anti-THSD7A antibody transfer. Finally, interactome analysis identified a protein complex, including THSD7A and integrin α3, linking THSD7A complexes to pathogenic regulation of cytoskeleton, adhesion, and membrane signaling in MN. Thus, anti-THSD7A antibodies induce profound molecular reconfiguration, including dysregulated proteolytic systems via a complement-independent pathway, revealing potential therapeutic targets in MN.

Authors

Ming Huang, Moritz Lassé, Silke Dehde, Felicitas E. Hengel, Fatih Demir, Anja M. Billing, Ning Song, Larissa Seifert, Oliver Kretz, Florian Grahammer, Ulf Panzer, Sebastian Brähler, Tobias B. Huber, Gunther Zahner, Markus M. Rinschen, Nicola M. Tomas

×

Figure 4

Proteome alterations in experimental THSD7A-associated MN.

Options: View larger image (or click on image) Download as PowerPoint
Proteome alterations in experimental THSD7A-associated MN.
(A and B) Vol...
(A and B) Volcano plots of the differential expression analysis from proteomic analysis of isolated glomeruli from control mice and Thsd7a–/– mice treated with control or anti-THSD7A IgG. In A, the control + anti-THSD7A IgG group was compared with the control + control IgG group, n = 7–8. In B, the Thsd7a–/–+ anti-THSD7A IgG group was compared with the control + anti-THSD7A IgG group, n = 7–8. X axis represents the log2FC of label-free quantification intensity of proteins by comparisons relatively, and y axis indicates the -log10 P value. Proteins marked in red or blue are significantly upregulated or downregulated, respectively (Benjamini-Hochberg–adjusted P < 0.05, |log2FC| > 0.5). (C) Heatmap of protein expression showing row-wise z scores of normalized intensities (group means from 7–8 replicates per group) across the 4 treatment groups. The heatmap includes all proteins that were significantly regulated in the control + anti-THSD7A IgG group versus control + control IgG group. (D) Venn diagram showing the significant proteins upregulated in control + anti-THSD7A IgG versus control + control IgG groups and downregulated in Thsd7a–/–+ anti-THSD7A IgG versus control + anti-THSD7A IgG groups. (E) Venn diagram showing the significant proteins downregulated in control + anti-THSD7A IgG versus control + control IgG groups and upregulated in Thsd7a–/– + anti-THSD7A IgG versus control + anti-THSD7A IgG groups. (F) Heatmap showing row-standardized protein expression (z scores of normalized intensities) of podocyte slit diaphragm proteins, podocyte adhesion proteins, and actin binding or cytoskeleton proteins. (G) GO-BP, KEGG, and Reactome enrichment analysis of proteins significantly regulated in comparisons of control + anti-THSD7A IgG versus control + control IgG or Thsd7a–/– + anti-THSD7A versus control + anti-THSD7A IgG groups, using fgsea (adjusted P < 0.05).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts